Latest Regulatory Engagement News

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

MyEco Group reveals a strategic pivot towards expanding its MyEco branded products, achieving a 9% sales increase in FY25, and implementing a $2.5 million cost-saving operational restructure aimed at EBITDA breakeven in FY26.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

NuEnergy Gas Limited has completed drilling three wells and commenced initial gas sales at its Tanjung Enim PSC in Indonesia, marking a key step toward full-scale production. Regulatory approvals and commercial agreements are advancing, positioning the company for growth in the unconventional gas sector.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Pilot Energy has made significant strides in its offshore Perth Basin exploration with environmental approval for a major seismic survey and secured substantial financing to support its ongoing projects and transition to clean energy.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Heavy Minerals Limited is finalising its Port Gregory Garnet Project Pre-Feasibility Study with a report due in November 2025, while advancing a promising industrial minerals project towards a binding agreement expected this quarter.

Santana Minerals reports robust progress on its Bendigo-Ophir Gold Project with an updated Pre-Feasibility Study, strategic land acquisitions, and a substantial capital raise, positioning the project for development in 2026.